Psoriasis Clinical Trials in Los Angeles

Showing 81-100 of 174 trials

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

NCT04152382

This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month for each participant. As part of protocol addendum, this study is additionally evaluating the safety and tolerability of LY3509754 in participants with psoriasis. Blood tests will be done to check how much LY3509754 is in the bloodstream and how long the body takes to get rid of it. The addendum will last up to 12 weeks for each participant.

Psoriasis

Eli Lilly and Company30 participantsStarted Nov 2019

Los Angeles, California, United States • Miami, Florida, United States • Miami, Florida, United States +10 more locations

COMPLETEDPhase 3< 1 mile

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

NCT01232283

This study will evaluate the effects of an experimental (being tested) study drug called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study is to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study will test efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.

Plaque Psoriasis

Amgen413 participantsStarted Nov 2010

Phoenix, Arizona, United States • Hot Springs, Arkansas, United States • Bakersfield, California, United States +43 more locations

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

Psoriasis Trials in Other Cities

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

CP-690-550 Ointment For Chronic Plaque Psoriasis

AMG 827 in Subjects With Psoriatic Arthritis

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Topical CP-690,550 For Chronic Plaque Psoriasis

PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Other Conditions in Los Angeles